Evidence map›Paper›PMID 38384499›Full record

ArticleInfection and drug resistance2024

CTX-M, TEM, and SHV Genes in

Margaret Lubwama, David P Kateete, George Katende, Edgar Kigozi, Jackson Orem, Warren Phipps, Freddie Bwanga

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Multidrug-Resistant and Potentially PathogenicFoods (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Genomic insights into extended-spectrumJournal of medical microbiology · 2025
    Article
  16. Genomic characterization ofFrontiers in microbiology · 2025
    Article
  17. Third-Generation Cephalosporin-Resistant UropathogenicThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  18. Article
  19. Article
  20. Infections withJournal of clinical medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Margaret LubwamaDepartment of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0003-4706-6157
David P KateeteDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
George KatendeDepartment of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Edgar KigoziDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Jackson OremUganda Cancer Institute, Kampala, Uganda.
Warren PhippsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Freddie BwangaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-8898-0992
Makerere University · UGUganda Cancer Institute · UGUniversity of Washington · US

Funding

Expanding independent research capacity in HIV-associated malignancies in UgandaD43TW009759 · FIC · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OREM, JACKSON, PHIPPS, WARREN · 2014 to 2023
$3.0M
FIC NIH HHS D43 TW009759
6 · The paper itself

Abstract

Purpose: We determined the phenotypic resistance to third-generation cephalosporins, phenotypic extended spectrum beta-lactamase (ESBL) prevalence, and genotypic prevalence of ESBL-encoding genes Patients and Methods: Blood cultures from hematologic cancer patients with febrile neutropenia were processed in BACTEC 9120. Results: Two hundred and two patients were included in the study. Median age of patients was 19 years (IQR: 10-30 years). Majority (N=119, 59%) were male patients. Sixty (30%) of the participants had at least one febrile episode due to Enterobacteriaceae. Eighty-three organisms were isolated with Conclusion: ESBL-producing Enterobacteriaceae are a predominant cause of bacteremia in hematologic cancer patients at UCI. The most common ESBL-encoding gene identified in the ESBL-PE was

Indexed as

antimicrobial resistancecancerCTX-Menterobacteriaceaeextended spectrum beta-lactamasesUganda

Identifiers

PMID38384499
PMCPMC10878986
OpenAlexW4391886795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.